Analysis reveals telmisartan's potential in targeting growth factors for chronic heart failure, suggesting promising outcomes compared to sorafenib.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Prajapati et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: